Azaserine
SIGMA/A1164 - Hybri-Max™, γ-irradiated, 50x, lyophilized powder, BioXtra, suitable for hybridoma
Synonym: O-Diazoacetyl-L-serine
CAS Number: 115-02-6
Empirical Formula (Hill Notation): C5H7N3O4
Molecular Weight: 173.13
EC Number: 204-061-6
MDL Number: MFCD00036802
Linear Formula: C5H7N3O4
Product Type: Chemical
| antibiotic activity spectrum | fungi |
| form | lyophilized powder |
| grade | Hybri-Max™ |
| impurities | endotoxin, tested |
| InChI | 1S/C5H7N3O4/c6-3(5(10)11) |
| InChI key | MZZGOOYMKKIOOX-VKHMYHEASA |
| mode of action | enzyme | inhibits |
| product line | BioXtra |
| Quality Level | 200 ![]() |
| SMILES string | N[C@@H](COC(=O)C=[N+]=[N- |
| sterility | γ-irradiated |
| storage temp. | −20°C |
| technique(s) | cell culture | hybridoma: suitable |
| Application: | For use in hybridoma cell culture applications as a myeloma selection agent. Used to study inhibition of formylglycinamide ribonucleotide amidotransferase and PRPP amidotransferase. |
| Biochem/physiol Actions: | Azaserine is an antibiotic, generated by Streptomyces fragilis. It is considered as a potential mutation inducing agent. It is known to promote pancreatic cancer and induces adenoma and carcinoma in vivo and in vitro. Azaserine also stimulates kidney and liver tumors in rats. |
| General description: | Chemical structure: amino acid derivatives |
| Legal Information: | Hybri-Max is a trademark of Sigma-Aldrich Co. LLC |
| Preparation Note: | Reconstitute contents of vial with 10 mL sterile cell culture medium. Stock solution is sufficient to prepare 500 mL medium. Final working concentration: 5.7 μM azaserine. |
| Symbol | ![]() GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 - H351 |
| Precautionary statements | P201 - P301 + P310 + P330 |
| Hazard Codes | T |
| Risk Statements | 25-40 |
| Safety Statements | 53-36/37/39-45 |
| RIDADR | UN 3462 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352207 |



